Vaccines for preventing pneumococcal infection in adults

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Moberley, Sarah ^a   Holden, John ^b   Tatham, David Paul ^b   Andrews, Ross M ^a  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b Garswood Surgery   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; ALL CAUSE MORTALITY; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; DEATH; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HIGH INCOME COUNTRY; HUMAN; LOW INCOME COUNTRY; META ANALYSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; AGED; CASE CONTROL STUDY; MIDDLE AGED; PROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIA;

ADULT; AGED; CASE-CONTROL STUDIES; HUMANS; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84874814058     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000422.pub3     Document Type: Review

References (117)

1. Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, et al.Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61:189-95.
2. Austrian R. Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines. Journal of Infectious Diseases 1977;136(Suppl):38-42.
3. Austrian R. Vaccines of pneumococcal capsular polysaccharides and the prevention of pneumococcal pneumonia. In: Beers RF Jr, Bassett EG editor(s). The Role of Immunological Factors in Infections, Allergic and Autoimmune Processes. New York: Raven Press, 1976:Chapter 8, 79-89.
4. Austrian R, Douglas RM, Schiffman G, Cietzee AM, Koornhof HJ, Hayden-Smith S, et al.Prevention of pneumococcal pneumonia by vaccination. Transactions of the Association of American Physicians 1976;89:184-94.
5. Klugman KP, Hayden Smith SW, Koornhof HJ. Evidence that prevention of carriage by pneumococcal capsular vaccines may be the mechanism of protection from pneumococcal pneumonia. South African Journal of Epidemiology and Infection 2011;26(4):221-4.
6. Austrian R. Surveillance of pneumococcal infection for field trials of polyvalent pneumococcal vaccines. National Institute of Allergy and Infectious Diseases 1980:184-94.
7. Austrian R. Surveillance of pneumococcal infection for field trials of polyvalent pneumococcal vaccines. National Institute of Allergy and Infectious Diseases 1980:184-94.
8. Benin AL, O'Brien KL, Watt JP, Reid R, Zell R, Katz S, et al.Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. Journal of Infectious Diseases 2003;188:81-9.
9. Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest 1987;92:204-12.
10. Dominguez A, Salleras L, Fedson D, Izquierdo C, Ruiz L, Ciruela P, et al.Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case control study. Clinical Infectious Diseases 2005;40:1250-7.
11. Furomoto A, Ohkusa Y, Chen M, Kawakami K, Masaki H, Sueyasu Y, et al.Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008;26:4284-9.
12. Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Bru JP, Stahl JP, et al.Clinical trial of an anti-pneumococcal vaccine in elderly people living in institutions. Revue d'Epidemiologie et de Sante Publique 1985;33:437-44.
13. Jackson L, Neuzil K, Yu O, Benson P, Barlow W, Adams A, et al.Effectiveness of pneumococcal polysaccharide vaccine in older adults. New England Journal of Medicine 2003;348(18):1747-55.
14. Kaufman P. Pneumonia in old age. Archives of Internal Medicine 1947;79:518-31.
15. Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, et al.Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 2010;28(43):7063-9.
16. Klastersky J, Mommen P, Cantraine F, Safary A. Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. European Journal of Cancer and Clinical Oncology 1986;22:807-13.
17. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. American Journal of Medicine 1997;103:281-90.
18. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal 1987;136:361-5.
19. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, et al.Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010;340:1004.
20. Ortqvist A, Hedlund J, Burman LA, Elbel E, Margareta H, Leinonen M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351:399-403.
21. Riley ID, Andrews M, Howard R, Tarr PI, Pfeiffer M, Challands P, et al.Immunization with polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977;1(8026):1338-41.
22. Shapiro E, Clemens J. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Annals of Internal Medicine 1984;101(3):325-30.
23. Shapiro E, Berg A, Austrian R, Schoeder B, Parcells V, Margolis B, et al.The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New England Journal of Medicine 1991;325(21):1453-60.
24. Simberkoff M, Cross A, Al-Ibrahim M, Baltch A, Geiseler P, Nadler J. Efficacy of pneumococcal vaccine in high-risk patients. New England Journal of Medicine 1986;315:1318-27.
25. Sims R, Steinmann W, McConville M, King L, Zwick W, Scwartz S. The clinical effectiveness of pneumococcal vaccine in the elderly. Annals of Internal Medicine 1988;108(5):653-7.
26. Smit P, Oberholzer D, Hayden-Smith S, Koornhof H, Hilleman M. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977;238:2613-6.
27. Smit P, Oberholzer D, Hayden-Smith S, Koornhof H, Hilleman M. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977;238:2613-6.
28. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, Vilanova A, Rodriguez T, Llor C, et al.Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clinical Infectious Diseases 2006;43:860-8.
29. Amman AJ, Addiego J, Wara DW, Lubin B, Smith WB, Mentzer WC. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anaemia and patients with splenectomy. New England Journal of Medicine 1977;297:879-900.
30. Ansaldi F, Turello V, Lai P, Bastone G, De Luca S, Rosselli R, et al.Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study. Journal of International Medical Research 2005;33(5):490-500.
31. Austrian R. Maxwell Finland Lecture: random gleanings from a life with the pneumococcus. Journal of Infectious Diseases 1975;131:474-84.
32. Bentley DW, Ha K, Mamot K, Moon D, Moore L, Poletto P, et al.Pneumococcal vaccine in the institutionalized elderly: design of a non-randomized trial and preliminary results. Reviews of Infectious Diseases 1981;Suppl 3:71-81.
33. Blay A, Bessler H, Lahad A, Waitman DA, Djaldetti M. Does pneumococcal vaccine reduce influenza morbidity in humans?. Vaccine 2007;25:1071-5.
34. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF 3rd, et al.Pneumococcal vaccine efficacy in selected populations in the United States. Annals of Internal Medicine 1986;104:1-6.
35. Breiman RF, Keller DW, Phelan MA, Sniadack DH, Stephens DS, Rimland D, et al.Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Archives of Internal Medicine 2000;160:2633-8.
36. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. New England Journal of Medicine 1980;303(10):549-52.
37. Butler J, Breiman R, Campbell J, Lipman H, Broome C, Facklam R. Polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826-31.
38. Chang YC, Chou YJ, Liu JY, Yeh TF, Huang N. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan - a representative population-based comparative study. Journal of Infection 2012;65(3):231-8.
39. Chiba H, Ohrui T, Matsui T, Fukushima T, Sasaki H. Benefits of pneumococcal vaccination for bedridden patients. Journal of the American Geriatrics Society 2004;52(8):1410.
40. Chintu C, Gupta K, Osborne C, Masona J. Clinical trial of the protective role of polyvalent pneumococcal vaccine in sickle cell anaemia patients in Zambia. Medical Journal of Zambia 1983;17:73-6.
41. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001;357:1008-11.
42. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventative effect of influenza and pneumococcal vaccines in elderly persons. European Respiratory Journal 2004;23:363-8.
43. Christenson B, Pauksen K, Sylvan SPE. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virology Journal 2008;5(52):1-9.
44. Douglas RM, Miles HB. Vaccination against streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. Journal of Infectious Diseases 1984;149:861-9.
45. Douglas RM, Hansman D, McDonald B, Paton J, Kirke K. Pneumococcal vaccine in Aboriginal children - a randomised controlled trial involving 60 children. Community Health Studies 1989;10:189-96.
46. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE, Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clinical Infectious Diseases 2001;32(5):794-800.
47. Farr BM, Johnston LJ, Cobb DK, Fisch MJ, Germanson TP, Adal KA, et al.Preventing pneumococcal bacteraemia in patients at risk: results of a matched case-control study. Archives of Internal Medicine 1995;155:2336-40.
48. Fletcher TJ, Tunnicliffe WS, Hammond K, Roberts K, Ayres JG. Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. BMJ 1997;314:1663-5.
49. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. American Journal of Medicine 1987;83(3):425-30.
50. Franzen D. Clinical efficacy of pneumococcal vaccination-a prospective study in patients with longstanding emphysema and/or bronchitis. European Journal of Medical Research 2000;5(12):537-40.
51. Gilbertson DTG, Arneson H, Collins TJ, Allan J. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. Nephrology Dialysis Transplantation 2011;26(9):2934-9.
52. Hedlund J, Christenson B, Lundbergh P, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow up. Vaccine 2003;21:3906-11.
53. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, et al.Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999;17:2493-500.
54. Karma P, Pukander J, Sipila M, Timonen M, Pontynen S, Herva E, et al.Prevention of otitis media in children by pneumococcal vaccination. American Journal of Otolaryngology 1985;6:173-84.
55. Kaufman P. Studies on old age pneumonia. Archives of Internal Medicine 1941;67:304-19.
56. Lamontagne F, Garant M, Carvalho J, Lanthier L, Smieja M, Pilon D. Pneumococcal vaccination and risk of myocardial infarction. Canadian Medical Association Journal 2008;179(8):773-7.
57. Lindenburg C, Langendam M, Benthem B, Miedema F, Coutinho R. No evidence that vaccination with a polysaccharide pneumococcal vaccine protects drug users against all-cause pneumonia. AIDS 2001;15(10):1315-7.
58. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. Journal of Experimental Medicine 1945;82:445-65.
59. Manzur A, Ruiz C, Sousa L, Bayas D, Celorrio J, Miguel J, et al.Influence of prior pneumococcal and influenza vaccination on outcomes of older adults with community-acquired pneumonia. Journal of the American Geriatrics Society 2011;59(9):1711-6.
60. MMWR. Outbreak of pneumococcal pneumonia among unvaccinated residents of a nursing home - New Jersey. MMWR Weekly 2001;50(33):707-10.
61. Mykietiuk A, Carratala J, Dominguez A, Manzur A, Fernandez-Sabe N, Dorca J, et al.Effect of prior pneumococcal vaccination on clinical outcome of hospitalised adults with community-acquired pneumococcal pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 2006;25:457-62.
62. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999;17(Suppl):91-3.
63. Nichol KL, Baken L, Whorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Archives of Internal Medicine 1999;159:2437-42.
64. Ochoa-Gondara O, Vila-Corcoles A, Ansaa X, Rodriguez-Blancob T, Salsencha E, De Diegoa C, et al.Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine 2008;26(16):1955-62.
65. Rodriguez-Barradas MC, Goulet J, Brown S, Bidwell Goetz M, Rimland D, Simberkoff MS, et al.Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clinical Infectious Diseases 2008;46:1093-100.
66. Rosen C, Christensen P, Hovelius B, Prellner K. Effect of pneumococcal vaccination on upper respiratory tract infections in children. Scandinavian Journal of Infectious Diseases 1983;39:39-44.
67. Schembri S, Morant S, Winter JH, MacDonald TM. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax 2009;64:567-72.
68. Skull SA, Andrews RM, Byrnes GB, Heath A, Kelly HA, Nolan TM, et al.Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine 2007;25:4631-40.
69. Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease - the effect of ongoing, systemic steroid treatment. Vaccine 2006;24:1408-12.
70. Sumitani M, Tochino Y, Kamimori T, Fujiwara H, Fujikawa T. Additive inoculation of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients. Internal Medicine 2008;47:1189-97.
71. Teramoto S, Yamamoto H, Yamaguchi Y, Hanaoka Y, Ishii M, Ouchi Y, et al.Clinical efficacy of anti-pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference 2007;175:A137.
72. Vila-Corcolesa A, Salsencha E, Rodriguez-Blancob T, Ochoa-Gondara O, De Diegoa C, Valdiviesoa A, et al.Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 2009;27:1504-10.
73. Vila-Corcoles A, Ochoa-Gondar O, Guzmán JA, Rodriguez-Blanco T, Salsench E, Fuentes CM, et al.Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infectious Diseases 2010;10(73):1-8.
74. Wagner C, Popp W, Posch M, Vlasich C, Rosenberger-Spitzy A. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology 2003;49(4):246-50.
75. Ya Tseimakh I, Martynenko I, Paraeva S. Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal 2006;28(Suppl 50):1091.
76. Ryan M. Pneumococcal vaccine to counter emerging infectious disease threat in the military. Military Medicine 2001;166:1087-90.
77. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Annals of Internal Medicine 1964;60:759-66.
78. Butler J. Epidemiology of pneumococcal disease. In: Tuomanen E, Mitchell T, Morrison D, Spratt B editor(s). The Pneumococcus. 1st Edition. Vol. 10, Washington DC: American Society for Microbiology, 2004:148-68.
79. Casadevall A, Scharff M. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrobial Agents and Chemotherapy 1994;38:1695-702.
80. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004;22:3214-24.
81. Cook IF, Pond D, Hartel G. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2007;25(25):4767-74.
82. Cornu C, Yzebe D, Léophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of the pneumococcal polysaccharide vaccine in Immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001;19:4780-90.
83. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. BMJ Publication Group, 2001.
84. Fedson DS. Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996. Clinical Infectious Diseases 1998;26:1117-23.
85. Fedson DS, Scott JA, Scott G. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999;17(Suppl 1):11-8.
86. Fedson D, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analysis of pneumococcal vaccine in elderly and high risk adults. Vaccine 2004;22:927-46.
87. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, et al.Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Archives of Internal Medicine 1994;154:2666-77.
88. Fraser C, Murray A, Burr J. Identifying observational studies of surgical interventions in MEDLINE and EMBASE. BMC Medical Research Methodology 2006;6:41.
89. Hanna J, Wenck D, Murphy D. Three fatal pneumococcal polysaccharide vaccine failures. Medical Journal of Australia 2000;173:305-7.
90. Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, et al.Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Medicine 2009;6(5):e1000081.
91. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
92. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Canadian Medical Association Journal 2009;180:48-58.
93. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Meta analysis. Canadian Family Physician 1999;15:2381-93.
94. Jackson LA, Bensen P, Sneller VP, Bulter JC, Thompson RS, Chen RT, et al.Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-8.
95. Jefferson T. Pneumococcal vaccines: confronting the confounders. The Lancet 2009;373(9680):2008-9.
96. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD004876.pub3]
97. Klugman KP, Hayden Smith SW, Koornhof HJ. Evidence that prevention of carriage by pneumococcal capsular vaccines may be the mechanism of protection from pneumococcal pneumonia. South African Journal of Epidemiology and Infection 2011;26(4):221-4.
98. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org. Chichester, UK: Wiley-Blackwell, 2011.
99. Louie L, Rutherford G. Pneumococcal vaccine for prevention of Streptococcus pneumoniae infection in HIV infected persons. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD002236]
100. Makela P, Kayhty H. Vaccine-induced immunity to pneumococcal infection. In: Tuomanen E, Mitchell T, Morrison D, Spratt B editor(s). The Pneumococcus. 1st Edition. Vol. 25, Washington DC: American Society for Microbiology Press, 2004:403-20.
101. McMahon B, Parkinson A, Bulkow L, Davidson M, Wainwright K, Wolfe P, et al.Immunogenicity of the 23-valent pneumococcal polysaccharide vaccine in Alaska native chronic alcoholics compared with non-alcoholic native and non-native controls. American Journal of Medicine 1993;95(6):589-94.
102. Menzies R, McIntyre P, Beard F. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 1999 to 2002. Communicable Disease Intelligence 2004;28(Suppl):29-31.
103. Moore A, Wiffen P, Lipsky B. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC 2000;1(1):1-10.
104. Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine 1999;17(Suppl):79-84.
105. Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, et al.Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. Journal of Infectious Diseases 2010;201:516-24.
106. Pandey J. Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 2000;19:613-7.
107. Puig-Barbera J, Belenguer Varea A, Goterris Pinto M, Brines Benlliure MJ. Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis. Atencion Primaria 2002;30(5):269-81; discussion 281-3.
108. Reacher MH, Shah A, Livermore DM, Wale MCJ, Graham C, Johnson AP, et al.Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000;320:213-6.
109. Rello J, Lujan M, Gallego M, Valles J, Belmonte Y, Fontanals D, et al.Why mortality is increased in health-care-associated pneumonia; lessons from pneumococcal bacteremic pneumonia. Chest 2010;137:1138-44.
110. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
111. Tomasz A. The pneumococcus at the gates. New England Journal of Medicine 1995;333:514-5.
112. Walters J, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD001390.pub2]
113. Watson I, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002;20(17-8):2166-73.
114. Whitney C, Farley M, Hadler J, Harrison L, Bennett N, Lynfield R, et al.Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine 2003;348:1737-46.
115. Wright A, Morgan P, Canto M, Colebrook M, Dogson R, Lond M. Observations on the prophylactic inoculation against pneumococcus infections and on the results which have been achieved by it. Lancet 1914;183:87-96.
116. Dear K, Andrews R, Holden J, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD000422.pub2]
117. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD000422.pub2]